Get the latest news, insights, and market updates on ACHV (Achieve Life Sciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, announced today that the company will be hosting in-person one-on-one meetings coinciding with the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. Dec 17, 2025 - $ACHV
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
SEATTLE and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that the company has issued inducement grants of stock options to Erik Atkisson, Chief Legal Officer, and other new employees. As an inducement to employment, Achieve’s Board of Directors granted Mr. Atkisso Dec 8, 2025 - $ACHV
FDA Accepts Achieve Life Sciences, Inc. (ACHV) NDA Application for Cytisinicline in Smoking Cessation
Achieve Life Sciences Inc. (NASDAQ:ACHV) is one of the Canadian penny stocks to buy right now. Lake Street’s Thomas Flaten maintained a Buy rating on Achieve Life Sciences Inc. (NASDAQ:ACHV) at $11.00 on November 7. A day earlier, on November 6, the company confirmed that the US Food and Drug Administration has accepted its New […] Nov 25, 2025 - $ACHV
ACHV: FDA’s CNPV Awarded for Vaping
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter results, wrapping up an intense three months since its prior quarterly release. Since August, Achieve has communicated the acceptance of its new drug application (NDA), the assignment of a target action date for cytisinicline, the addition of new executives, Nov 10, 2025 - $ACHV
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping CessationConference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced its finan Nov 6, 2025 - $ACHV
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation
120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced several milestones in its ORCA-OL long Nov 3, 2025 - $ACHV
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025
SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its third quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 6, 2025, at 8:30 AM EST. To access Oct 29, 2025 - $ACHV
Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 High-Potential Small-Caps With Market Cap Under $1B. We came across a bullish thesis on Achieve Life Sciences, Inc. on DF Research’s Substack by Keith Dalrymple. In this article, we will summarize the bulls’ […] Oct 22, 2025 - $ACHV
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple